Pfizer Enters Autoimmune CAR T Therapy Market with $2.6 Billion Deal with China's Starna Therapeutics
Trendline

Pfizer Enters Autoimmune CAR T Therapy Market with $2.6 Billion Deal with China's Starna Therapeutics

What's Happening? Pfizer is making a significant entry into the in vivo CAR T therapy space for autoimmune diseases through a deal with China's Starna Therapeutics, potentially valued at up to $2.6 billion. The agreement includes an upfront payment of $330 million and up to $2.3 billion in milestone
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.